These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11033575)

  • 1. Numerical methods for the evaluation of individual bioequivalence criteria.
    Kimanani EK; Lavigne J; Potvin D
    Stat Med; 2000 Oct; 19(20):2775-95. PubMed ID: 11033575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subject-by-formulation interaction in determinations of individual bioequivalence: bias and prevalence.
    Endrenyi L; Tothfalusi L
    Pharm Res; 1999 Feb; 16(2):186-90. PubMed ID: 10100301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of the estimated variance component for subject-by-formulation interaction in studies of individual bioequivalence.
    Endrenyi L; Taback N; Tothfalusi L
    Stat Med; 2000 Oct; 19(20):2867-78. PubMed ID: 11033581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case studies, practical issues and observations on population and individual bioequivalence.
    Zariffa NM; Patterson SD; Boyle D; Hyneck M
    Stat Med; 2000 Oct; 19(20):2811-20. PubMed ID: 11033577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bootstrap procedure in individual bioequivalence.
    Shao J; Chow SC; Wang B
    Stat Med; 2000 Oct; 19(20):2741-54. PubMed ID: 11033572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Applying multilevel models in evaluation of bioequivalence (I)].
    Liu QL; Shen ZZ; Chen F; Li XS; Yang M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Dec; 30(12):1302-6. PubMed ID: 20193320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of some properties of individual bioequivalence (IBE) from replicate-design studies.
    Tothfalusi L; Endrenyi L
    Int J Clin Pharmacol Ther; 2001 Apr; 39(4):162-6. PubMed ID: 11332872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small sample confidence interval approach to assess individual bioequivalence.
    Hyslop T; Hsuan F; Holder DJ
    Stat Med; 2000 Oct; 19(20):2885-97. PubMed ID: 11033583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some statistical considerations on the FDA draft guidance for individual bioequivalence.
    Hsuan FC
    Stat Med; 2000 Oct; 19(20):2879-84. PubMed ID: 11033582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On statistical power for average bioequivalence testing under replicated crossover designs.
    Wan H; Chow SC
    J Biopharm Stat; 2002 Aug; 12(3):295-309. PubMed ID: 12448572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of multilevel models in the evaluation of bioequivalence (II).].
    Liu QL; Shen ZZ; Li XS; Chen F; Yang M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Mar; 31(3):333-9. PubMed ID: 20510066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population and individual bioequivalence: lessons from real data and simulation studies.
    Zariffa NM; Patterson SD
    J Clin Pharmacol; 2001 Aug; 41(8):811-22. PubMed ID: 11504268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bootstrap in bioequivalence studies.
    Pigeot I; Hauschke D; Shao J
    J Biopharm Stat; 2011 Nov; 21(6):1126-39. PubMed ID: 22023681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of individual bioequivalence: occasion-to-occasion versus mean switchability.
    Kimanani EK
    Stat Med; 2000 Oct; 19(20):2797-810. PubMed ID: 11033576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An individual bioequivalence criterion: regulatory considerations.
    Chen ML; Patnaik R; Hauck WW; Schuirmann DJ; Hyslop T; Williams R
    Stat Med; 2000 Oct; 19(20):2821-42. PubMed ID: 11033578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Professor Endrenyi's Legacy: An Evaluation of the Regulatory Requirement "Fixed Effects, Rather Than Random Effects, Should Be Used for All Terms".
    Fuglsang A
    J Pharm Pharm Sci; 2021; 24():413-420. PubMed ID: 34343469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the repeated cross-over design in assessing bioequivalence: (within and between subjects variability - Schuirmann Confidence Intervals estimation).
    Le Roux Y; Guimart C; Tenenhaus M
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):339-45. PubMed ID: 9725503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual bioequivalence testing under 2x3 designs.
    Chow SC; Shao J; Wang H
    Stat Med; 2002 Mar; 21(5):629-48. PubMed ID: 11870806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.